{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:31:19Z","timestamp":1793039479747,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04418-1","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:45:30Z","timestamp":1768455930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hereditary ovarian cancer"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2227-8079","authenticated-orcid":false,"given":"Weronika Anna","family":"Jurgiel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Panasiuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Posmyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"issue":"2","key":"4418_CR1","first-page":"93","volume":"22","author":"AT Ali","year":"2023","unstructured":"Ali AT, Al-Ani O, Al-Ani F. Epidemiology and risk factors for ovarian cancer. Prz Menopauzalny. 2023;22(2):93\u2013104.","journal-title":"Prz Menopauzalny"},{"issue":"1","key":"4418_CR2","first-page":"49","volume":"85","author":"AT Aus","year":"2020","unstructured":"Aus AT. Can we prevent ovarian cancer? Ceska Gynekol. 2020;85(1):49\u201358.","journal-title":"Ceska Gynekol"},{"issue":"6","key":"4418_CR3","doi-asserted-by":"publisher","first-page":"522","DOI":"10.2174\/1568009618666180102103008","volume":"18","author":"AT Ali","year":"2018","unstructured":"Ali AT. Towards prevention of ovarian cancer. Curr Cancer Drug Targets. 2018;18(6):522\u201337.","journal-title":"Curr Cancer Drug Targets"},{"issue":"4","key":"4418_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.21037\/cco-20-34","volume":"9","author":"P Gaona-Luviano","year":"2020","unstructured":"Gaona-Luviano P, Medina-Gaona LA, Maga\u00f1a-P\u00e9rez K. Epidemiology of ovarian cancer. Chin Clin Oncol. 2020;9(4):47.","journal-title":"Chin Clin Oncol"},{"issue":"Pt 3","key":"4418_CR5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.semcancer.2022.03.027","volume":"86","author":"E Schoutrop","year":"2022","unstructured":"Schoutrop E, Moyano-Galceran L, Lheureux S, Mattsson J, Lehti K, Dahlstrand H, et al. Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment. Semin Cancer Biol. 2022;86(Pt 3):207\u201323.","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"4418_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.5306\/wjco.v14.i2.40","volume":"14","author":"EN Imyanitov","year":"2023","unstructured":"Imyanitov EN, Kuligina ES, Sokolenko AP, Suspitsin EN, Yanus GA, Iyevleva AG, et al. Hereditary cancer syndromes. World J Clin Oncol. 2023;14(2):40\u201368.","journal-title":"World J Clin Oncol"},{"issue":"2 Pt 1","key":"4418_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/AOG.0b013e31825f3576","volume":"120","author":"KA Schrader","year":"2012","unstructured":"Schrader KA, Hurlburt J, Kalloger SE, Hansford S, Young S, Huntsman DG, et al. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. Obstet Gynecol. 2012;120(2 Pt 1):235\u201340.","journal-title":"Obstet Gynecol"},{"issue":"3","key":"4418_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5603\/NJO.2023.0026","volume":"73","author":"U Wojciechowska","year":"2023","unstructured":"Wojciechowska U, Bara\u0144ska K, Miklewska M, Didkowska JA. Cancer incidence and mortality in Poland in 2020. Nowotwory J Oncol. 2023;73(3):129\u201345.","journal-title":"Nowotwory J Oncol"},{"issue":"44","key":"4418_CR9","doi-asserted-by":"publisher","first-page":"18032","DOI":"10.1073\/pnas.1115052108","volume":"108","author":"T Walsh","year":"2011","unstructured":"Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(44):18032\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"4418_CR10","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/jama.295.12.1379","volume":"295","author":"T Walsh","year":"2006","unstructured":"Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006;295(12):1379\u201388.","journal-title":"JAMA"},{"issue":"5","key":"4418_CR11","first-page":"255","volume":"5","author":"A Doraczy\u0144ska-Kowalik","year":"2020","unstructured":"Doraczy\u0144ska-Kowalik A, Janus-Szyma\u0144ska G, Matkowski R, Micha\u0142owska D, S\u0105siadek MM. Genetyka i onkologia (cz\u0119\u015b\u0107 2.). Podstawy Medycyny personalizowanej w Leczeniu Raka Piersi i Raka Jajnika. Biul Polskiego Towarzystwa Onkologicznego Nowotwory. 2020;5(5):255\u201372.","journal-title":"Biul Polskiego Towarzystwa Onkologicznego Nowotwory"},{"issue":"5","key":"4418_CR12","doi-asserted-by":"publisher","first-page":"362","DOI":"10.7326\/0003-4819-143-5-200509060-00012","volume":"143","author":"HD Nelson","year":"2005","unstructured":"Nelson HD, Huffman LH, Fu R, Harris EL, U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive services task force. Ann Intern Med. 2005;143(5):362\u201379.","journal-title":"Ann Intern Med"},{"key":"4418_CR13","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3389\/fonc.2020.00361","volume":"10","author":"Y Hatano","year":"2020","unstructured":"Hatano Y, Tamada M, Matsuo M, Hara A. Molecular trajectory of BRCA1 and BRCA2 mutations. Front Oncol. 2020;10:361.","journal-title":"Front Oncol"},{"issue":"1","key":"4418_CR14","first-page":"57","volume":"5","author":"AG Knudson","year":"1978","unstructured":"Knudson AG. Retinoblastoma: a prototypic hereditary neoplasm. Semin Oncol. 1978;5(1):57\u201360.","journal-title":"Semin Oncol"},{"key":"4418_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13053-016-0046-5","volume":"14","author":"P Wojcik","year":"2016","unstructured":"Wojcik P, Jasiowka M, Strycharz E, Sobol M, Hodorowicz-Zaniewska D, Skotnicki P, et al. Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland. Hered Cancer Clin Pract. 2016;14:5.","journal-title":"Hered Cancer Clin Pract"},{"issue":"2","key":"4418_CR16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5114\/pjp.2019.82905","volume":"70","author":"A Kowalik","year":"2019","unstructured":"Kowalik A, Zalewski K, Kopczy\u0144ski J, Sio\u0142ek M, Lech M, Hi\u0144cza K, et al. Somatic mutations in BRCA1&2 in 201 unselected ovarian carcinoma samples - single institution study. Pol J Pathol. 2019;70(2):115\u201326.","journal-title":"Pol J Pathol"},{"issue":"7","key":"4418_CR17","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1002\/cam4.748","volume":"5","author":"M Koczkowska","year":"2016","unstructured":"Koczkowska M, Zuk M, Gorczynski A, Ratajska M, Lewandowska M, Biernat W, et al. Detection of somatic BRCA1\/2 mutations in ovarian cancer \u2013 next-generation sequencing analysis of 100 cases. Cancer Med. 2016;5(7):1640\u20136.","journal-title":"Cancer Med"},{"issue":"4","key":"4418_CR18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.7326\/M13-2747","volume":"160","author":"VA Moyer","year":"2014","unstructured":"Moyer VA, U.S. Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive services task force recommendation statement. Ann Intern Med. 2014;160(4):271\u201381.","journal-title":"Ann Intern Med"},{"issue":"3","key":"4418_CR19","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","volume":"20","author":"KP Pennington","year":"2014","unstructured":"Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764\u201375.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"4418_CR20","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1200\/JCO.19.02960","volume":"38","author":"PA Konstantinopoulos","year":"2020","unstructured":"Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J Clin Oncol. 2020;38(11):1222\u201345.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4418_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.molonc.2009.02.004","volume":"3","author":"HT Lynch","year":"2009","unstructured":"Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M, et al. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol. 2009;3(2):97\u2013137.","journal-title":"Mol Oncol"},{"issue":"1","key":"4418_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer. J Mol Diagn. 2017;19(1):4\u201323.","journal-title":"J Mol Diagn"},{"issue":"2","key":"4418_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3390\/genes15020219","volume":"15","author":"V Barili","year":"2024","unstructured":"Barili V, Ambrosini E, Bortesi B, Minari R, Sensi ED, Cannizzaro IR, et al. Genetic basis of breast and ovarian cancer: approaches and lessons learnt from three decades of inherited predisposition testing. Genes. 2024;15(2):219.","journal-title":"Genes"},{"issue":"4","key":"4418_CR24","first-page":"280","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280\u2013304.","journal-title":"CA Cancer J Clin"},{"issue":"3\u20134","key":"4418_CR25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10689-004-9545-z","volume":"3","author":"J Charrow","year":"2004","unstructured":"Charrow J. Ashkenazi Jewish genetic disorders. Fam Cancer. 2004;3(3\u20134):201\u20136.","journal-title":"Fam Cancer"},{"issue":"3","key":"4418_CR26","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s13167-010-0037-y","volume":"1","author":"R Janavi\u010dius","year":"2010","unstructured":"Janavi\u010dius R, Founder. BRCA1\/2 mutations in the europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J. 2010;1(3):397\u2013412.","journal-title":"EPMA J"},{"issue":"2","key":"4418_CR27","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/1097-0142(20010715)92:2<440::AID-CNCR1340>3.0.CO;2-O","volume":"92","author":"AY Bahar","year":"2001","unstructured":"Bahar AY, Taylor PJ, Andrews L, Proos A, Burnett L, Tucker K, et al. The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi jews: implications for the generality of U.S. Population data. Cancer. 2001;92(2):440\u20135.","journal-title":"Cancer"},{"issue":"6","key":"4418_CR28","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1086\/302922","volume":"66","author":"B G\u00f3rski","year":"2000","unstructured":"G\u00f3rski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, et al. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet. 2000;66(6):1963\u20138.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"4418_CR29","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/ijc.11338","volume":"106","author":"J Menkiszak","year":"2003","unstructured":"Menkiszak J, Gronwald J, G\u00f3rski B, Jakubowska A, Huzarski T, Byrski T, et al. Hereditary ovarian cancer in Poland. Int J Cancer. 2003;106(6):942\u20135.","journal-title":"Int J Cancer"},{"key":"4418_CR30","unstructured":"Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJ, editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993 [cited 2024 Sep 8]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1247\/"},{"issue":"3","key":"4418_CR31","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/cge.12360","volume":"87","author":"M Szwiec","year":"2015","unstructured":"Szwiec M, Jakubowska A, G\u00f3rski B, Huzarski T, Tomiczek-Szwiec J, Gronwald J, et al. Recurrent mutations of BRCA1 and BRCA2 in poland: an update. Clin Genet. 2015;87(3):288\u201392.","journal-title":"Clin Genet"},{"issue":"7","key":"4418_CR32","doi-asserted-by":"publisher","first-page":"e0201086","DOI":"10.1371\/journal.pone.0201086","volume":"13","author":"A Kowalik","year":"2018","unstructured":"Kowalik A, Sio\u0142ek M, Kopczy\u0144ski J, Krawiec K, Kalisz J, Zi\u0119ba S, et al. BRCA1 founder mutations and beyond in the Polish population: A single-institution BRCA1\/2 next-generation sequencing study. PLoS ONE. 2018;13(7):e0201086.","journal-title":"PLoS ONE"},{"issue":"4","key":"4418_CR33","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3390\/cancers13040849","volume":"13","author":"A \u0141ukomska","year":"2021","unstructured":"\u0141ukomska A, Menkiszak J, Gronwald J, Tomiczek-Szwiec J, Szwiec M, Jasi\u00f3wka M, et al. Recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish patients with ovarian cancer. Cancers (Basel). 2021;13(4):849.","journal-title":"Cancers (Basel)"},{"key":"4418_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13053-017-0085-6","volume":"16","author":"C Heramb","year":"2018","unstructured":"Heramb C, Wangensteen T, Grindedal EM, Ariansen SL, Lothe S, Heimdal KR, et al. BRCA1 and BRCA2 mutation spectrum - an update on mutation distribution in a large cancer genetics clinic in Norway. Hered Cancer Clin Pract. 2018;16:3.","journal-title":"Hered Cancer Clin Pract"},{"issue":"5","key":"4418_CR35","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/(SICI)1097-0215(20000601)86:5<737::AID-IJC21>3.0.CO;2-1","volume":"86","author":"M Van Der Looij","year":"2000","unstructured":"Van Der Looij M, Szabo C, Besznyak I, Liszka G, Csokay B, Pulay T, et al. Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. Int J Cancer. 2000;86(5):737\u201340.","journal-title":"Int J Cancer"},{"issue":"6","key":"4418_CR36","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1086\/301880","volume":"62","author":"P Huusko","year":"1998","unstructured":"Huusko P, P\u00e4\u00e4kk\u00f6nen K, Launonen V, P\u00f6yh\u00f6nen M, Blanco G, Kauppila A, et al. Evidence of founder mutations in Finnish BRCA1 and BRCA2 families. Am J Hum Genet. 1998;62(6):1544\u20138.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"4418_CR37","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/1897-4287-4-4-193","volume":"4","author":"NY Krylova","year":"2006","unstructured":"Krylova NY, Lobeiko OS, Sokolenko AP, Iyevleva AG, Rozanov ME, Mitiushkina NV, et al. BRCA1 4153delA founder mutation in Russian ovarian cancer patients. Hered Cancer Clin Pract. 2006;4(4):193\u20136.","journal-title":"Hered Cancer Clin Pract"},{"issue":"3","key":"4418_CR38","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10549-008-0190-3","volume":"117","author":"L Papi","year":"2009","unstructured":"Papi L, Putignano AL, Congregati C, Zanna I, Sera F, Morrone D, et al. Founder mutations account for the majority of BRCA1-attributable hereditary breast\/ovarian cancer cases in a population from Tuscany, central Italy. Breast Cancer Res Treat. 2009;117(3):497\u2013504.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"4418_CR39","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/humu.9015","volume":"19","author":"US Khoo","year":"2002","unstructured":"Khoo US, Chan KYK, Cheung ANY, Xue WC, Shen DH, Fung KY, et al. Recurrent BRCA1 and BRCA2 germline mutations in ovarian cancer: a founder mutation of BRCA1 identified in the Chinese population. Hum Mutat. 2002;19(3):307\u20138.","journal-title":"Hum Mutat"},{"issue":"5","key":"4418_CR40","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1086\/302099","volume":"63","author":"PN Tonin","year":"1998","unstructured":"Tonin PN, Mes-Masson AM, Futreal PA, Morgan K, Mahon M, Foulkes WD, et al. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet. 1998;63(5):1341\u201351.","journal-title":"Am J Hum Genet"},{"issue":"3","key":"4418_CR41","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10549-015-3629-3","volume":"154","author":"J Dutil","year":"2015","unstructured":"Dutil J, Golubeva VA, Pacheco-Torres AL, Diaz-Zabala HJ, Matta JL, Monteiro AN. The spectrum of BRCA1 and BRCA2 alleles in Latin America and the caribbean: a clinical perspective. Breast Cancer Res Treat. 2015;154(3):441\u201353.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"4418_CR42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/ng0596-117","volume":"13","author":"S Thorlacius","year":"1996","unstructured":"Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet. 1996;13(1):117\u20139.","journal-title":"Nat Genet"},{"issue":"4","key":"4418_CR43","doi-asserted-by":"publisher","first-page":"R284","DOI":"10.1186\/bcr785","volume":"6","author":"EK Mikaelsdottir","year":"2004","unstructured":"Mikaelsdottir EK, Valgeirsdottir S, Eyfjord JE, Rafnar T. The Icelandic founder mutation BRCA2 999del5: analysis of expression. Breast Cancer Res. 2004;6(4):R284\u2013290.","journal-title":"Breast Cancer Res"},{"issue":"24","key":"4418_CR44","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.21037\/atm-20-1582","volume":"8","author":"RC Bonadio","year":"2020","unstructured":"Bonadio RC, Crespo JR, Estevez-Diz MDP. Ovarian cancer risk assessment in the era of next-generation sequencing. Ann Transl Med. 2020;8(24):1704.","journal-title":"Ann Transl Med"},{"key":"4418_CR45","doi-asserted-by":"publisher","first-page":"e201204005","DOI":"10.5936\/csbj.201204005","volume":"1","author":"SL Clark","year":"2012","unstructured":"Clark SL, Rodriguez AM, Snyder RR, Hankins GDV, Boehning D. Structure-Function of the tumor suppressor BRCA1. Comput Struct Biotechnol J. 2012;1:e201204005.","journal-title":"Comput Struct Biotechnol J"},{"issue":"4","key":"4418_CR46","first-page":"862","volume":"23","author":"U Varol","year":"2018","unstructured":"Varol U, Kucukzeybek Y, Alacacioglu A, Somali I, Altun Z, Aktas S, et al. BRCA genes: BRCA 1 and BRCA 2. J BUON. 2018;23(4):862\u20136.","journal-title":"J BUON"},{"issue":"9","key":"4418_CR47","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.7150\/jca.30410","volume":"10","author":"I Gorodetska","year":"2019","unstructured":"Gorodetska I, Kozeretska I, Dubrovska ABRCA, Genes. The role in genome Stability, cancer stemness and therapy resistance. J Cancer. 2019;10(9):2109\u201327.","journal-title":"J Cancer"},{"issue":"1","key":"4418_CR48","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.critrevonc.2008.06.003","volume":"69","author":"A Russo","year":"2009","unstructured":"Russo A, Cal\u00f2 V, Bruno L, Rizzo S, Bazan V, Di Fede G. Hereditary ovarian cancer. Crit Rev Oncol\/Hematol. 2009;69(1):28\u201344.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"45","key":"4418_CR49","doi-asserted-by":"publisher","first-page":"e31705","DOI":"10.1097\/MD.0000000000031705","volume":"101","author":"C Xie","year":"2022","unstructured":"Xie C, Luo J, He Y, Jiang L, Zhong L, Shi Y. BRCA2 gene mutation in cancer. Med (Baltim). 2022;101(45):e31705.","journal-title":"Med (Baltim)"},{"issue":"Suppl 6","key":"4418_CR50","doi-asserted-by":"publisher","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","volume":"24","author":"JA Ledermann","year":"2013","unstructured":"Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi24\u201332.","journal-title":"Ann Oncol"},{"issue":"1Suppl 1","key":"4418_CR51","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/ijgo.13878","volume":"155","author":"JS Berek","year":"2021","unstructured":"Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021;155(1Suppl 1):61\u201385.","journal-title":"Int J Gynaecol Obstet"},{"issue":"1","key":"4418_CR52","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/GCO.0000000000000340","volume":"29","author":"PT Kroeger","year":"2017","unstructured":"Kroeger PT, Drapkin R. Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol. 2017;29(1):26\u201334.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"5","key":"4418_CR53","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/PAP.0b013e3181b4fffa","volume":"16","author":"R Vang","year":"2009","unstructured":"Vang R, Shih IM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009;16(5):267\u201382.","journal-title":"Adv Anat Pathol"},{"issue":"11","key":"4418_CR54","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.3390\/diagnostics12112619","volume":"12","author":"C Mustafin","year":"2022","unstructured":"Mustafin C, Vesnin S, Turnbull A, Dixon M, Goltsov A, Goryanin I. Diagnostics of ovarian tumors in postmenopausal patients. Diagnostics (Basel). 2022;12(11):2619.","journal-title":"Diagnostics (Basel)"},{"issue":"11","key":"4418_CR55","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","volume":"31","author":"F Mosele","year":"2020","unstructured":"Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group. Ann Oncol. 2020;31(11):1491\u2013505.","journal-title":"Ann Oncol"},{"issue":"1","key":"4418_CR56","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","volume":"81","author":"AJ Cortez","year":"2018","unstructured":"Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018;81(1):17\u201338.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"4418_CR57","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.hoc.2018.07.010","volume":"32","author":"B Orr","year":"2018","unstructured":"Orr B, Edwards RP. Diagnosis and treatment of ovarian cancer. Hematol Oncol Clin North Am. 2018;32(6):943\u201364.","journal-title":"Hematol Oncol Clin North Am"},{"key":"4418_CR58","doi-asserted-by":"publisher","first-page":"564601","DOI":"10.3389\/fcell.2020.564601","volume":"8","author":"M Rose","year":"2020","unstructured":"Rose M, Burgess JT, O\u2019Byrne K, Richard DJ, Bolderson E. PARP inhibitors: clinical Relevance, mechanisms of action and tumor resistance. Front Cell Dev Biol. 2020;8:564601.","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"4418_CR59","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","volume":"18","author":"DM O\u2019Malley","year":"2023","unstructured":"O\u2019Malley DM, Krivak TC, Kabil N, Munley J, Moore KN. PARP inhibitors in ovarian cancer: A review. Target Oncol. 2023;18(4):471\u2013503.","journal-title":"Target Oncol"},{"issue":"10","key":"4418_CR60","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.21873\/anticanres.14606","volume":"40","author":"V Mitsopoulos","year":"2020","unstructured":"Mitsopoulos V, Innamaa A, Lippiatt J, Plevris N, Biliatis I. Radical surgical procedures in advanced ovarian cancer and differences between primary and interval debulking surgery. Anticancer Res. 2020;40(10):5869\u201375.","journal-title":"Anticancer Res"},{"issue":"3","key":"4418_CR61","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/COC.0000000000000262","volume":"41","author":"G Siesto","year":"2018","unstructured":"Siesto G, Cavina R, Romano F, Vitobello D. Primary debulking surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A Propensity-matched analysis. Am J Clin Oncol. 2018;41(3):280\u20135.","journal-title":"Am J Clin Oncol"},{"key":"4418_CR62","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.bpobgyn.2016.10.017","volume":"41","author":"L Andrews","year":"2017","unstructured":"Andrews L, Mutch DG. Hereditary ovarian cancer and risk reduction. Best Pract Res Clin Obstet Gynaecol. 2017;41:31\u201348.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"2","key":"4418_CR63","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/tbm\/iby101","volume":"10","author":"MK Ladd","year":"2018","unstructured":"Ladd MK, Peshkin BN, Senter L, Baldinger S, Isaacs C, Segal H, et al. Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer. Transl Behav Med. 2018;10(2):337\u201346.","journal-title":"Transl Behav Med"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04418-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04418-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04418-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T14:11:08Z","timestamp":1770646268000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04418-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4418"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04418-1","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"260"}}